Article Text
Abstract
Donor-funded research is research funded by private donors in exchange for research-related benefits, such as trial participation or access to the trial intervention. This has been pejoratively referred to as ‘pay to play’ research, and criticised as unethical. We outline three models of donor-funded research, and argue for their permissibility on the grounds of personal liberty, their capacity to facilitate otherwise unfunded health research and their consistency with current ethical standards for research. We defend this argument against objections that donor-funded research is wrongly exploitative, unfair and undermines the public good of medical research. Our conclusion is that, like all human subjects research, donor-funded research should be regulated via standard health research legislation/guidelines and undergo Research Ethics Committee/Institutional Review Board and scientific peer-review. We expect that, measured against these standards, some donor-funded research would be acceptable.
- research ethics
- clinical trials
- drugs and drug industry
- research on special populations
- ethics committees/consultation
Statistics from Altmetric.com
Footnotes
Contributors MK and AB made a substantial, and equal, contribution to the conception of the work, each draft, revision and approval of final content. Both authors agree to be accountable for all aspects of the work and ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Funding This research received no specific grant from any funding agency in thepublic, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
- From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Fair subject selection in clinical research: formal equality of opportunity
- Beyond informed consent: the therapeutic misconception and trust
- Philanthropy on trial: can the rich rescue shelved compounds?
- Equity of resource flows for reproductive, maternal, newborn, and child health: are those most in need being left behind?
- Phase I oncology trials: why the therapeutic misconception will not go away
- Fair and equitable subject selection in concurrent COVID-19 clinical trials
- Stakeholder perceptions of current practices and challenges in priority setting for non-communicable disease control in Kenya: a qualitative study